Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774604 | 0.90 | HTR6 (0.46) | PIK3C3HTR6KDM1ASLC22A12DRD2 | |
| SCHEMBL30774371 | 0.88 | PIK3C3 (0.44) | PIK3C3HTR6KDM1ASLC22A12HTR1A | |
| SCHEMBL30774608 | 0.88 | HTR6 (0.50) | PIK3C3HTR6KDM1ASLC22A12HTR1A | |
| SCHEMBL30774525 | 0.87 | KDM1A (0.47) | PIK3C3HTR6KDM1ASLC22A12CYP11B2 | |
| SCHEMBL30774373 | 0.87 | HTR6 (0.55) | PIK3C3HTR6KDM1ASLC22A12DRD2 | |
| SCHEMBL30774596 | 0.85 | KDM1A (0.51) | PIK3C3HTR6KDM1ASLC22A12CYP11B2 | |
| SCHEMBL30774386 | 0.85 | PIK3C3 (0.44) | PIK3C3HTR6KDM1ASLC22A12CYP11B2 | |
| SCHEMBL30774362 | 0.84 | MET (0.50) | PIK3C3HTR6KDM1A | |
| SCHEMBL30774381 | 0.83 | PIK3C3 (0.44) | PIK3C3HTR6KDM1ASLC22A12 | |
| SCHEMBL30774504 | 0.81 | SLC22A12 (0.51) | PIK3C3HTR6KDM1ASLC22A12IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | claimed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | claimed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024061371-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州威诺森医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | PIK3C3 1913/4885HTR6 3964/4885KDM1A 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.